SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,472

Sector

Pharmaceuticals

Calendar

03-26 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-12	10.25 ¥	+0.10%	8,217,939
25-12-11	10.24 ¥	+0.79%	8,499,220
25-12-10	10.16 ¥	-0.39%	5,488,936
25-12-09	10.20 ¥	-0.78%	5,342,110
25-12-08	10.28 ¥	-0.48%	6,890,131

End-of-day quote Shanghai S.E., December 11, 2025

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2025-12-12			5-day change	1st Jan Change
10.25 ^CNY	+0.10%		-0.77%	-14.15%

12-12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
12-01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT

Capitalization	13.75B 1.95B 1.66B 1.55B 1.46B 2.69B 176B 2.93B 18.1B 7.02B 83.19B 7.31B 7.16B 304B	P/E ratio 2023	18x	P/E ratio 2024	14.8x
Enterprise value	7.24B 1.03B 874M 817M 769M 1.41B 92.97B 1.55B 9.53B 3.7B 43.82B 3.85B 3.77B 160B	EV / Sales 2023	0.69x	EV / Sales 2024	0.87x
Free-Float	41.74%	Yield 2023	1.02%	Yield 2024	2.51%

12-12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
12-01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT
11-04	Shyndec Pharmaceutical Buys Rights for Lactulose Oral Solution	MT
10-29	Henan Yangsen Pharmaceutical Group Co., Ltd. completed the acquisition of an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd..	CI
10-29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
10-17	Henan Yangsen Pharmaceutical Group Co., Ltd. agreed to acquire an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd. for approximately CNY 110 million.	CI
10-13	Shyndec Pharmaceutical's Unit Gets Nod to Market Sitagliptin Phosphate	MT
09-23	Shyndec Pharmaceutical's Subsidiary Gets Nod to Add Specification to Vitamin B6 Injection	MT
09-18	Shyndec Pharma's Enalapril Maleate Tablets Passes Regulator's Consistency Evaluation	MT
09-17	Shyndec Pharmaceutical Gets Registration Certification for Penehyclidine Hydrochloride Injection	MT
09-01	Shyndec Pharma Obtains Drug Registration for Chest Pain Drug	MT
08-29	Shanghai Shyndec Pharmaceutical H1 net profit down 6.5% Y/Y	RE
08-08	Shyndec Pharma's Unit Gets Nod to Market Ketamine Hydrochloride	MT

1 day	+0.10%
1 week	-0.77%
Current month	-0.39%
1 month	-4.30%
3 months	-7.91%
6 months	-5.36%
Current year	-14.15%

Shanghai Shyndec Pharmaceutical Co., Ltd. Stock

Equities

600420

CNE000001JG2

Pharmaceuticals

Valuation: Shanghai Shyndec Pharmaceutical Co., Ltd.

Chart: Shanghai Shyndec Pharmaceutical Co., Ltd.

Latest news: Shanghai Shyndec Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shanghai Shyndec Pharmaceutical Co., Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 week	10.09	10.37
1 month	10.09	10.74
Current year	9.69	12.01
1 year	9.69	12.42
3 years	7.61	14.41
5 years	7.61	14.41
10 years	7.61	18.5

Manager	Title	Age	Since
Jing Zu DFI	Director of Finance/CFO	55	-
Qian Yin Jing IRC	Investor Relations Contact	45	2019-09-12
Zhong Xi Zhang SEC	Corporate Secretary	49	2024-03-27

Director	Title	Age	Since
Xiang Dong Yu BRD	Director/Board Member	61	2019-01-30
Peng Wang BRD	Director/Board Member	43	2022-11-27
Yong Liu BRD	Director/Board Member	56	2021-05-16

	2023	2024
Net sales	12.07B 1.71B 1.46B 1.36B 1.28B 2.36B 155B 2.58B 15.89B 6.16B 73.04B 6.42B 6.28B 266B	10.94B 1.55B 1.32B 1.23B 1.16B 2.14B 140B 2.33B 14.4B 5.59B 66.19B 5.82B 5.69B 241B
Net income	692M 98.07M 83.54M 78.04M 73.43M 135M 8.88B 148M 911M 353M 4.19B 368M 360M 15.28B	1.08B 154M 131M 122M 115M 212M 13.91B 231M 1.43B 553M 6.56B 576M 564M 23.92B
Net Debt	-4.83B -684M -583M -545M -512M -943M -61.98B -1.03B -6.36B -2.47B -29.22B -2.57B -2.51B -107B	-6.51B -922M -785M -734M -690M -1.27B -83.51B -1.39B -8.56B -3.32B -39.37B -3.46B -3.39B -144B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+0.10%	-0.77%	-16.39%	+1.49%	1.95B
MERCK KGAA	-0.38%	-1.86%	-17.29%	-34.93%	60.15B
KYOWA KIRIN CO., LTD.	+1.03%	+0.41%	+5.82%	-17.63%	8.58B
HALOZYME THERAPEUTICS, INC.	+0.50%	-1.77%	+29.60%	+5.55%	7.32B
SK BIOPHARMACEUTICALS CO., LTD.	-1.84%	-0.60%	+26.86%	+82.47%	7.06B
YUHAN CORPORATION	+0.86%	-0.26%	+0.09%	+122.78%	5.91B
INDIVIOR PLC	-0.64%	+1.25%	+207.35%	+61.64%	4.44B
BETTA PHARMACEUTICALS CO., LTD.	-0.87%	+0.06%	-12.91%	-6.25%	2.84B
SUPERNUS PHARMACEUTICALS, INC.	+1.40%	+3.24%	+30.38%	+33.60%	2.7B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+0.87%	-1.80%	+17.83%	+39.46%	2.5B
Average	+0.10%	-0.07%	+27.13%	+28.82%	10.35B
Weighted average by Cap.	-0.17%	-1.10%	+3.82%	-4.40%